
    
      This is an open-label single-dose study in healthy participants. All participants will
      receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per
      kilogram (mg/kg) over 60 minutes on Day 1. After the administration of study drug on Day 1,
      participants will stay in the clinical study unit until being discharged after the
      assessments on Day 2. Participants will be required to return to the study center for
      outpatient visits including safety assessments through Day 85 after study drug
      administration. Participants' safety will be monitored throughout the study.
    
  